©The Author(s) 2017.
World J Gastroenterol. Mar 7, 2017; 23(9): 1618-1626
Published online Mar 7, 2017. doi: 10.3748/wjg.v23.i9.1618
Published online Mar 7, 2017. doi: 10.3748/wjg.v23.i9.1618
Table 1 Baseline characteristics
| Number of patients | 664 |
| Age (mean, yr) | 56.7% |
| Gender | |
| Female | 42.8% |
| Male | 57.2% |
| Race | |
| Caucasian | 83.4% |
| African American or Black | 6.44% |
| Asian American | 1.89% |
| American Indian or Alaska Native | 0.30% |
| Other and unavailable | 7.97% |
| Ethnicity | |
| Hispanic | 13.6% |
| Non-Hispanic | 86.4% |
| Number of patients on DAAs | |
| LDV/SOF | 369% |
| OBV/PTV/r + DSV | 48% |
| SIM/SOF | 114% |
| SOF/RBV | 133% |
| Fibrosis stage | |
| ≤ Stage 2 (minimal to moderate fibrosis) | 35.8% |
| Stage 3 (advanced fibrosis) | 10.8% |
| Stage 4 (cirrhosis) | 51.5% |
| Unknown or unavailable | 1.90% |
- Citation: Langness JA, Nguyen M, Wieland A, Everson GT, Kiser JJ. Optimizing hepatitis C virus treatment through pharmacist interventions: Identification and management of drug-drug interactions. World J Gastroenterol 2017; 23(9): 1618-1626
- URL: https://www.wjgnet.com/1007-9327/full/v23/i9/1618.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i9.1618